Industries > Emerging and Midsize CROs
Activate Remote, Always-on Workflows with Your Sponsors and Sites and Streamline TMF Workflows
Emerging and midsize contract research organizations (CROs) demand software that is flexible, scalable, and intuitive. Florence offers two solutions to streamline your workflows. Standardize your Trial Master File on the Florence eTMF, and integrate directly with your study sites with remote, always-on access on Florence’s SiteLink™.

Built to help you manage study operations on a global scale –
whether you’re running 1 study at 10 sites or 10 studies at 1,000 sites.
How Florence Helps Emerging and Midsize Contract Research Organizations

Maximize CRA Efficiency
CRAs with remote access capabilities can monitor over 60 sites per week with Florence. CRA staffing bottlenecks and travel costs are reduced, and CRAs can make a greater impact on study sites.

Make Sites Happier
When you partner with Florence to deploy research workflows to your sites, you give them a platform they love. Florence eBinders is ranked #1 for clinical trial workflows by sites for ease-of-use, ease-of-setup and support.

Improve eTMF Quality
Over 80% of your eTMF is generated at the trial site. By integrating site workflows with your eTMF through Florence, you can exchange documents seamlessly. The eTMF pass rate of one customer increased from 65% to 98.7%.

Differentiate with Sponsors
Differentiate with study speed, site satisfaction and transparency by enabling remote, always-on, controlled workflows and access for sites and sponsors.

Accelerate Study Timelines
Automated workflows like electronic logs, placeholders, eSignatures and quality assurance workflows reduce start-up times by 40% for most of our customers and accelerate overall study timelines to reduce time to submission.

Activate Sites Fast
Coupling our existing global network of connected sites with our #1-ranked site activation team, we set up your sites in days with a 92%+ site adoption rate on Florence eBinders™, the industry-standard eISF and Electronic Participant Binder for sites.
“Our highest performing CRAs are now ‘visiting’ 64 sites per week with remote monitoring on Florence, up from 2 per week.”
VP Clin Ops, Top 3 Global CRO
“92% of 140 study sites in 8 countries were activated on Florence for remote source access and monitoring in four weeks.”
VP Clin Ops, Top 3 Pharma
“Our eTMF QA score went from a 65% submission pass rate to 98.7% by having real-time remote access to the site eISF.”
Aperio Clinical Outcomes
According to user reviews, Florence is rated the #1 clinical trial workflows platform for ease-of-setup, ease-of-use and customer support.
Why being rated #1 out of 190 clinical trial platforms on G2, the peer-to-peer review site, matters for you.
We are committed to making you and your sites successful.
We are committed to making you and your sites successful.
Clinical Trial Workflow Products for Emerging and Midsize Sponsors
Florence’s SiteLink™
Remote, Always-On Research Workflows with Your Study Sites
Activate remote site start-up, monitoring, and source data review/verification on SiteLink. Connect and deploy Florence eBinders™, the industry-standard electronic Investigator Site File and Electronic Participant Binder, on a global scale to every site in your study.
Florence’s eTMF
Scalable Trial Master File with Integrated Site Access
Get set up fast with the top-rated platform in ease-of-use, ease-of-setup, and customer support. Plus, connect directly to your sites with the only eTMF integrated with the industry-standard electronic investigator site file network.
In clinical research, compliance is crucial. We’ve got you covered.






Why Emerging and Midsize Biopharma and Medical Device Companies Rely on Florence for Their Study Workflows
Scales as You Scale
Whether you’re running a single study at a dozen sites or 100 studies at a thousand, we offer solutions that can fit your size, budget and capabilities. Our expert implementation and support teams handle all the heavy lifting so you and your sites are up and running as soon as possible.
Global Infrastructure
Today, research is conducted on a global scale, spanning borders, time zones, and regulatory agencies. Florence’s global reach – 10,000 sites in 45 countries – along with a team of regulatory experts and granular access controls enable you to deploy digital infrastructure around the world.
Industry Leader in Support
You benefit from the experience of a team of experts who have helped more than 10,000 clinical trial sites and 30,000 users migrate to digital workflows. This deep understanding of what makes a site successful allows us to provide the most comprehensive support in the industry.
Sites Trust Florence
Sites are tired of sponsors forcing ill-fitting software into their workflows. As a result, sponsors rarely see the value they expect. Florence changes this by designing software for site-first workflows. And they trust us. We’re ranked #1 for clinical trial workflows by sites for ease-of-use, ease-of-setup and support.
Top Ranked Ease-of-use
When you establish continuous, remote workflows across many study sites around the world, you need an easy-to-use platform. With Florence, you and your sites won’t have to deal with the complex interfaces often associated with clinical software and can instead focus on getting the work done quickly.
Access to the World’s Leading Sites
The world’s leading academic medical centers, cancer institutes, hospitals, healthcare networks, site networks, and independent sites rely on Florence for their workflows. Through Florence, they make their workflows available to you directly.

Florence’s platform is helping Pfizer to respond to the changing environment due to COVID-19 and further progress COVID-19 research with the capability to perform remote monitoring where approved by regulatory authorities and ethics committees.

Rob Goodwin
VP and Head of Operations in Global Product Development
Pfizer
Florence Supports Site Enablement on a Global Scale
Florence now supports workflows between sponsors and more than 10,000 study sites in 45 countries.
